Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Why biosimilars should be interchangeable with biologics

Identical vials held by gloved hands

There is sufficient evidence to prove that biosimilars are equivalent to biologics and should be used interchangeably.

Biosimilar drugs — biologics designed to mimic an original product — continue to generate headlines on their potential for major cost savings. An audit recently reported in The BMJ[1] suggested that if all patients being treated with a monoclonal antibody received biosimilars, the NHS would save £3m a year – and with the same outcomes. The audit, conducted by the Royal College of Physicians (RCP)[2], found that infliximab biosimiliar drugs were equally effective and safe compared with patented infliximab.

These data add to a bank of information on biosimilars, including an analysis published in the Annals of Internal Medicine[3], which considered 19 eligible studies that compared pharmacokinetics, clinical efficacy, adverse events or immunogenicity of a biosimilar tumour necrosis factor-alpha (TNF-α) inhibitor with a reference biologic in humans. The researchers concluded that preliminary evidence supports the biosimilarity and interchangeability of biosimilar and reference TNF-α inhibitors, and their findings generated widespread press coverage, with pieces in Kaiser Health News[4], STAT News[5], Consumer Healthday[6], United Press International (UPI[7]) and the International Business Times[8]. The lead author, Caleb Alexander, told UPI that his study addresses a “billion dollar question” on the similarity of biosimilars and, “based on the available evidence”, he reasoned that the products studied “appeared comparable and they will definitely be cheaper”[7].

Despite Alexander’s conclusions, US regulators are struggling with the issue of interchangeability of biologics and biosimilars, on which the US Food and Drug Administration (FDA) has been accused of failing to provide sufficient guidance[9]. Pfizer’s Inflectra (infliximab-dyyb), for example, is biosimilar to Remicade (infliximab), but it is not considered an “interchangeable” product, so, in some US states, pharmacists will not be able to switch patients from Remicade to Inflectra. The cost saving potential of biosimilars is yet to be realised, and this lack of interchangeability is responsible[10].

Drug coverage is more politically natured in the United States than in most other developed countries owing to the power of the drug lobby, which spends considerable resources influencing national and state legislators and regulators. Efforts to advance the use of biosimilars and support the emerging biosimilar industry have been more successful in the EU, where the drug lobby is more restrained – biosimilars already on the market in Europe are estimated to be between 10% and 70% cheaper than their brand name counterparts[4].

Interchangeability of biosimilars could have a big impact on drug budgets around the world. According to health economist Austin Frakt[11], TNF-α inhibitor biologics such as Remicade or Enbrel – prescribed to treat rheumatoid arthritis, Crohn’s disease, psoriasis and a range of other autoimmune disorders – account for around one-fifth of all drug spending in the United States. The RCP’s report[2] estimates that if biosimilars were used in the UK instead of patented counterparts, the cost of treating irritable bowel disease could drop by 50%.

Global perspectives

The international biologics market may face turmoil if the drugs are deemed interchangeable while companies and payers adapt to saving tens of millions in annual drug budgets. The growing global expenditure on biologics is predicted to reach US$221bn in 2017[12], and an estimated US$71bn in patented biologics will see their patents expire by 2020[13] — these trends fuel the race to produce biosimilar products to sell at a discount and capture the market.

Interest is growing, but attitudes to biosimilars are different across the world. In the UK, according to NHS England: “The automatic substitution, defined here as the practice of dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber, is not appropriate for biological medicines, including biosimilar medicines and is not permitted at this time[14].”

In the EU, there has been a pathway for approving biosimilar medicines since 2003. The main part of the process is comparing the biosimilar with its reference medicine to show that there are no significant differences between them. The European Medicines Agency does not make recommendations on whether a biosimilar can be used interchangeably with its reference medicine, but it suggests that “for questions related to switching from one biological medicine to another, patients should speak to their doctor and pharmacist”[15].

Canada’s public health department Health Canada says it does not support automatically substituting biosimilars for brand-name biologics. Coverage decisions are made at the provincial level, but it is unknown whether provinces will make different decisions on substitution[16]. Australia’s Pharmaceutical Benefits Advisory Committee, however, recommends that biosimilars are suitable for substitution at the pharmacy level[17].

Protecting biologic market share

Insurers are among those most interested in the introduction of biosimilars, and while they encourage their use to control prices, drug companies (such as Amgen[18]) are, according to one analysis[19], “hedging their bets by crafting defensive strategies to protect sales of branded biologic drugs while also developing biosimilars of their own”.

Motives to protect the market share of brand-name biologics are controversial, but, suffice to say, opponents have made many other arguments against the introduction and coverage of biosimilars. Below are the main, often unsupported, criticisms hoped to slow down or derail the use of biosimilar products.

  • The science isn’t robust yet. Protectors of originator biologics often argue that the biosimilar manufacturers use science that is not as “robust”, employ lower-quality manufacturing standards, and produce products that cause more adverse effects. Some say that biosimilars are not as effective, nor as safe, as the branded drug they have been copied from, although this criticism is unjustified. Some consumers (and prescribers) still doubt the value of brand-name versus generic drugs – an issue being recycled for the biosimilar debate.
  • Variations are problematic. The US Biotechnology Innovation Organization says there are interchangeability issues with biosimilars. Its website states: “each individual biologic therapy is a complex, heterogeneous mixture, which, in many cases, cannot be well characterised by current science. Because of this complexity, even minor differences in manufacturing processes can cause variations in the end product[20].” But do these variations, if they exist, make any substantive difference to the health outcomes of the patient? Current research suggests that if there are variations, they are not a problem[21].
  • The regulators must differentiate distinctions between reference product, biosimilar and interchangeable. Some groups argue that there should be no substitution unless the FDA has designated a biologic product as interchangeable, a factor that will delay introduction of many biologics. Opponents typically reason that “interchangeability” is about patient safety. The US FDA[21], however, makes the distinctions clear: “There are two new types of biological products: biosimilar and interchangeable. Biosimilars are a type of biological product that are licensed (approved) by the FDA because they are highly similar to an already FDA-approved biological product, known as the biological reference product (reference product), and have been shown to have no clinically meaningful differences from the reference product.” A biosimilar is distinguished from an “interchangeable biological product”, which the FDA says “is expected to produce the same clinical result as the reference product in any given patient,” as well as “meeting the biosimilarity standard”.
  • The regulatory regimens must change to deal effectively with safety. Again, the Biotechnology Innovation Organization argues that the US FDA approves biologics on the basis of an “interchangeable status”, and it is state, not federal law, that governs whether one can be substituted by the other. Defenders of originator biologics argue that “in considering patient safety and pharmacovigilance monitoring, current state rules on substitution will likely need to be updated or completely re-written in the context of biosimilar and interchangeable biologic medicines”. This means more delay, more expense for health systems and more US patients unable to afford any biologic product.
  • It should be doctors, not payers, who decide which type of product a patient is given. This argument keeps the prescribing physician, who can be “educated” by biologic companies, in charge of any substitutions. This argument preys on the “doctor knows best” rule, and assumes the prescriber knows more about the products’ differences and designates the product he or she believes the patient should receive. Essentially, biologic defenders want doctors to instruct “dispense as written” or “brand medically necessary”, despite the unlikelihood of an underlying reason to justify these directions. This behaviour is already displayed by brand-name companies, which use their large marketing budgets to sway physicians and discredit the generic competition.
  • Consumers are ill-informed. Another argument suggests that consumers are uninformed about biosimilars and are easily exploited. A 2015 PWC survey[18] found that most consumers could not choose the correct definition of a biologic from a shortlist, but this lack of knowledge is not an acceptable reason for restricting the availability of cheaper biosimilars.

Delaying tactics

Under the guise of “patient protection”, the drug lobby uses an array of arguments to delay the introduction of biosimilars to the US market[22]. One argument suggests that the prescribing physician should be notified of the substitution because patients may react differently to different products. This argument claims that it is in the interest of public health for the physician to be informed which product is used, so adverse events can be attributed correctly. But this principle applies to all pharmaceuticals.

Second, the lobby argues that the patient, or the patient’s authorised representative, should, at a minimum, be notified of the substitution. This argument calls for heightened vigilance by patients, who should know exactly which product is being administered to discuss with the pharmacist or physician past treatment experiences so that any potential future problems can be avoided. Again, this is no different from other pharmaceutical prescribing in the context of good primary care.

Third, the pharmacist and the physician should keep records of the substitution. This argument states: many biologic medicines are used to treat chronic conditions that can change over time, so it is important for a patient’s treatment team to have records that document how and when a patient was treated with biologic therapies. These records will also provide insight down the road should an adverse reaction or disease evolution occur. Needless to say, proper record-keeping of patients’ medicines is already an essential part of modern medical care, so why bother with extra forms of medical record-keeping for these drugs?

Poor excuses

Pharma and the drug lobby are weak in their efforts to discredit biosimilars and imply lower levels of safety and tolerability compared with their originator products. Research suggests no substantive outcome differences between the use of originator biologics and their biosimilar counterparts, and arguments against their effectiveness and safety fall flat.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202121

Readers' comments (2)


    Unsuitable or offensive? Report this comment

  • The debate on the interchangeability of biosimilar drugs and the originator biological product must be informed and driven by the scientific data and regulatory opinion, rather than political or financial wishful thinking about the potential for controlling budgets or reducing spending. Unlike small molecule generics, biosimiliars are not identical to the originator and the scientific understanding of the effects of these small differences are not fully understood. In most cases the clinical efficacy and safety data underpinning biosimiliars is based on limited patient numbers and exposure times. In the absence of an equivalent extent of clinical safety data as the originator, or well designed interchangeability/ switching safety/ efficacy clinical studies, it is entirely justified to not to switch the treatment of existing patients between the originator and biosimiliars products or between different biosimiliars products

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.